Laura A Maile

age ~54

from Hillsborough, NC

Get Report

Also known as:

Laura N Maile
Loura A Maile

Phone and address:: 3920 Remington Run, Hillsborough, NC 27278
(919)2414662

Connected to:

Laura Maile Phones & Addresses

3920 Remington Run, Hillsborough, NC 27278 • (919)2414662
Carrboro, NC
9113 Coach Way, Chapel Hill, NC 27516 • (919)9422144

Work

Company:

Vascular pharmaceuticals, inc
2011
Position:

Head of research and product development

Education

School / High School:

University of North Carolina- Chapel Hill, NC
1998
Specialities:

Doctoral in Biochemistry

Resumes

Laura Maile Research Triangle Park, NC

view source

Work:

Vascular Pharmaceuticals, Inc

2011 to 2000
Head of Research and Product Development University of North Carolina
Chapel Hill, NC
2010 to 2011
Associate Professor Assistant Professor
2005 to 2010 Instructor
2004 to 2005 Research Associate
2002 to 2004

Education:

University of North Carolina
Chapel Hill, NC
1998 to 2002
Doctoral in Biochemistry University of Bristol
Bristol, CT
1995 to 1998
PhD in Biochemistry University of Bristol
Bristol, CT
1988 to 1991
BSc in Microbiology

Laura Maile

view source

Us Patents

Monoclonal Antibodies For Enhancing Or Inhibiting Insulin-Like Growth Factor-I
view source
US Patent:

8187595, May 29, 2012
Filed:

Jul 7, 2009
Appl. No.:

12/498719
Inventors:

David R. Clemmons - Chapel Hill NC, US
Laura A. Maile - Chapel Hill NC, US
Assignee:

The University of North Carolina at Chapel Hill - Chapel Hill NC
International Classification:

A61K 39/395
US Classification:

4241301, 4241411, 4241781
Abstract:

The present invention provides αVβ3 integrin cysteine loop domain agonists and antagonists (including peptide agonists and antagonists and analogs thereof), along with methods of using the same.

Methods For Inhibiting Diabetic Retinopathy With An Antibody Against Integrin Associated Protein (Iap)
view source
US Patent:

8613922, Dec 24, 2013
Filed:

Aug 26, 2011
Appl. No.:

13/219276
Inventors:

David R. Clemmons - Chapel Hill NC, US
Laura A. Maile - Chapel Hill NC, US
Assignee:

The University of North Carolina at Chapel Hill - Chapel Hill NC
International Classification:

A61K 39/00
A61K 39/395
A61K 39/38
US Classification:

4241391, 4241411, 4241841
Abstract:

A method of inhibiting cellular activation by insulin-like growth factor-1 (IGF-1) in a subject in need thereof (e. g. , a subject afflicted with cancer, atherosclerosis, diabetic retinopathy or other disease) comprises administering an antagonist that inhibits the binding of IAP to SHPS-1 to the subject in an amount effective to inhibit cellular activation by IGF-1. Compounds and compositions for carrying out such methods are also described.

Method For Enhancing Or Inhibiting Insulin-Like Growth Factor-I
view source
US Patent:

8206706, Jun 26, 2012
Filed:

Feb 18, 2009
Appl. No.:

12/388045
Inventors:

David R. Clemmons - Chapel Hill NC, US
Laura A. Maile - Chapel Hill NC, US
Assignee:

The University of North Carolina at Chapel Hill - Chapel Hill NC
International Classification:

A61K 39/395
US Classification:

4241301, 4241411
Abstract:

The present invention provides αVβ3 integrin cysteine loop domain agonists and antagonists (including peptide agonists and antagonists and analogs thereof), along with methods of using the same.

Method For Inhibiting Cellular Activation By Insulin-Like Growth Factor-1
view source
US Patent:

20040213792, Oct 28, 2004
Filed:

Apr 24, 2003
Appl. No.:

10/422588
Inventors:

David Clemmons - Chapel Hill NC, US
Laura Maile - Chapel Hill NC, US
International Classification:

A61K038/17
A61K039/395
US Classification:

424/155100, 514/012000
Abstract:

A method of inhibiting cellular activation by Insulin-like Growth Factor-1 (IGF-1) in a subject in need thereof (e.g., a subject afflicted with cancer, atherosclerosis or other disease) comprises administering an antagonist that inhibits the binding of IAP to SHPS-1 to the subject in an amount effective to inhibit cellular activation by IGF-1. Compounds and compositions for carrying out such methods are also described.

Method For Enhancing Or Inhibiting Insulin-Like Growth Factor-I
view source
US Patent:

20050288217, Dec 29, 2005
Filed:

May 6, 2005
Appl. No.:

11/123290
Inventors:

David Clemmons - Chapel Hill NC, US
Laura Maile - Chapel Hill NC, US
International Classification:

A61K038/16
US Classification:

514007000, 514012000, 514013000
Abstract:

The present invention provides αVβ3 integrin cysteine loop domain agonists and antagonists (including peptide agonists and antagonists and analogs thereof), along with methods of using the same.

Method For Inhibiting Cellular Activation By Insulin-Like Growth Factor-1
view source
US Patent:

20080160013, Jul 3, 2008
Filed:

Sep 28, 2007
Appl. No.:

11/863426
Inventors:

David R. Clemmons - Chapel Hill NC, US
Laura A. Maile - Chapel Hill NC, US
International Classification:

A61K 39/395
A61K 38/02
A61P 9/10
A61P 35/00
US Classification:

4241301, 514 2
Abstract:

A method of inhibiting cellular activation by Insulin-like Growth Factor-1 (IGF-1) in a subject in need thereof (e.g., a subject afflicted with cancer, atherosclerosis or other disease) comprises administering an antagonist that inhibits the binding of IAP to SHPS-1 to the subject in an amount effective to inhibit cellular activation by IGF-1. Compounds and compositions for carrying out such methods are also described.

Method For Inhibiting Cellular Activation By Insulin-Like Growth Factor-1
view source
US Patent:

20100215640, Aug 26, 2010
Filed:

Nov 12, 2009
Appl. No.:

12/617246
Inventors:

David R. Clemmons - Chapel Hill NC, US
Laura A. Maile - Chapel Hill NC, US
International Classification:

A61K 39/395
A61K 38/16
A61K 38/02
A61P 27/00
US Classification:

4241301, 514 12, 514 2
Abstract:

A method of inhibiting cellular activation by Insulin-like Growth Factor-1 (IGF-1) in a subject in need thereof (e.g., a subject afflicted with cancer, atherosclerosis, diabetic retinopathy or other disease) comprises administering an antagonist that inhibits the binding of IAP to SHPS-1 to the subject in an amount effective to inhibit cellular activation by IGF-1. Compounds and compositions for carrying out such methods are also described.

Monoclonal Antibodies For Enhancing Or Inhibiting Insulin-Like Growth Factor-I
view source
US Patent:

20120269816, Oct 25, 2012
Filed:

May 17, 2012
Appl. No.:

13/474294
Inventors:

David R. Clemmons - Chapel Hill NC, US
Laura A. Maile - Chapel Hill NC, US
International Classification:

A61K 39/395
A61P 27/02
US Classification:

4241391, 4241781
Abstract:

The present invention provides αVβ3 integrin cysteine loop domain agonists and antagonists (including peptide agonists and antagonists and analogs thereof), along with methods of using the same.

Classmates

Laura Maile (Highland)

view source

Schools:

Thorntown High School Thorntown IN 1964-1967

Community:

Cheryl Rose, Jim Linton, David Bush

Facebook

Laura Maile Blancq

view source

Friends:

Katie Aggen, Jean De La Tour, Vanessa Hansen Helms, Andy Hungerford, Ben Thurman

Mylife

Joseph Maile @ .com

view source

People Search Directory M Mahlangu, Fikile - Malinis, Laura Maile, Dorothy - Mailen ... Results for Joseph Maile Great news! MyLife has multiple entries for Joseph Maile.

Michelle Maile @ .com

view source

People Search Directory M Mahlangu, Fikile - Malinis, Laura Maile, Dorothy - Mailen ... Results for Michelle Maile Great news! MyLife has multiple entries for Michelle Maile.